Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + nab-paclitaxel + platinum as neoadjuvant therapy for resectable esophageal squamous cell carcinoma
ChiCTR2200060652Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Inner Mongolia Medical University
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Hospital of Inner Mongolia Medical University. Primary endpoint: pathologic complete response. Started Jan 2022; status: recruiting.
02
Drugs
camrelizumabpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200060652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060652.